Clinical Trial Update: SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma [Phase 2]

View source ↗

Summary

This Phase 2 trial compares SC-PEG Asparaginase to Oncaspar in pediatric acute lymphoblastic leukemia and lymphoblastic lymphoma, with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Lymphoblastic Lymphoma

Drugs mentioned

• Oncaspar (pegaspargase)
• SC-PEG Asparaginase (pegylated asparaginase)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-09-10